Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

12.64EUR
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
€12.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
208,195
52-wk High
€19.42
52-wk Low
€8.53

Latest Key Developments (Source: Significant Developments)

Medigene AG Says Raised 32.3 Mln EUros In Oversubscribed Private Placement
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::MEDIGENE SUCCESSFULLY RAISES EUR 32.3 MILLION IN OVERSUBSCRIBED PRIVATE PLACEMENT.ISSUED 2,230,000 NEW SHARES FROM AUTHORIZED CAPITAL, REPRESENTING APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARES.SHARES WERE ALLOCATED TO INSTITUTIONAL INVESTORS AT A PRICE OF EUR 14.50 PER SHARE.FINANCING WILL INCREASE TOTAL NUMBER OF REGISTERED SHARES TO 24,544,595.  Full Article

Germany's Medigene AG announces capital increase
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::SAYS MEDIGENE AG - MEDIGENE ANNOUNCES CAPITAL INCREASE TO FUND IMMUNOTHERAPY PROGRAMS.SAYS EXPECTS TO ISSUE UP TO 2.23 MILLION NEW SHARES FROM AUTHORIZED CAPITAL, WHICH REPRESENTS APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARE CAPITAL..  Full Article

Medigene Affirms FY Guidance
Wednesday, 9 May 2018 

May 9 (Reuters) - Medigene AG ::Q1 REVENUES UP 6 PERCENT AT 2.77 MILLION EUROS.Q1 EBITDA LOSS WIDENS BY 6 PERCENT TO 3.19 MILLION EUROS.AFFIRMS FY GUIDANCE FOR EBITDA LOSS OF 21 - 23 MILLION EUROS.SAYS HAS SUFFICIENT RESOURCES TO FUND BUSINESS OPERATIONS BEYOND THE PLANNING HORIZON OF 2 YRS.  Full Article

Medigene Sells US-Rights For Veregen, Raises 2017 Guidance
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MEDIGENE AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017.EXPECTS REVENUES OF EUR 10.5-11.5 M INSTEAD OF EUR 8-10 M AS PREVIOUSLY GUIDED.EXPECTS 2017 EBITDA-LOSS OF EUR 14-15 M INSTEAD OF EUR 16-18 M.EXPECTS 2017 CASH UTILIZATION OF EUR 20-22 M INSTEAD OF EUR 23-27 M.  Full Article

Medigene says 9M immunotherapy revenue 3.4 mln eur
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Medigene :Says confirms its financial guidance for 2017.Says 9M revenue from core business immunotherapies (bluebird bio partnership) of eur 3.435 million.Says 9M total revenue eur 7.176 million (9M 2016: eur 7.052 million).Says 9M EBITDA loss increased as planned to eur 10.143 million (9M 2016: eur 9.095 million).  Full Article

bluebird bio and Medigene establish strategic T cell receptor alliance
Thursday, 29 Sep 2016 

Medigene AG : bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy . Medigene will be responsible for generation and delivery of TCRs using its TCR isolation and characterization platform . Medigene will receive an upfront payment of $15 million .Medigene will receive research and development funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage.  Full Article

Medigene H1 total revenue up 62 pct at 5.5 mln euros
Friday, 5 Aug 2016 

Medigene AG : H1 total revenue increased by 62 pct to 5.470 million euros (6M 2015: 3.372 million euros) . H1 cash and cash equivalents and time deposits increased by 4 pct to 48.672 million euros (12/31/2015: 46.759 million euros) . Confirms its financial guidance for fiscal year 2016 . H1 research and development expenses increased by 23 pct to 5.079 million euros (6M 2015: 4.117 million euros) .H1 EBITDA loss reduced by 6 pct to 4.011 million euros (6M 2015: 4.251 million euros).  Full Article

German stocks - Factors to watch on May 25

FRANKFURT, May 25 The following are some of the factors that may move German stocks on Friday: